Limited Competition: Strategic Timing of Antiretroviral Treatment (START) (UM1)

Post Date

August 29th 2014

Application Due Date

November 19th 2014

Funding Opportunity Number

PAR-14-329

CFDA Number(s)

93.242
93.855
93.856

Funding Instrument Type(s)

Cooperative Agreement

Funding Activity Categories

Health

Eligibility Categories

Other

Other Eligible Applicants include the following: Only the current START awardee is eligible to apply to this limited competition FOA.

Funding

• Award Range:

  $None - $None

Grant Description

The purpose of this limited competition Funding Opportunity Announcement (FOA) is to continue support to complete the Strategic Timing of Antiretroviral Treatment (START) trial. START is a randomized clinical trial to determine if immediate initiation of antiretroviral treatment (ART) in HIV-positive patients is superior in delaying the occurrence of AIDS, non-AIDS events and death.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/pa-files/PAR-14-329.html